Core Insights - Editas Medicine, Inc. is set to present a digital poster at the American Heart Association (AHA) Scientific Sessions 2025, highlighting its innovative gene editing technology aimed at lowering LDL cholesterol levels [1][2]. Company Overview - Editas Medicine is a pioneering gene editing company focused on developing transformative in vivo medicines for serious diseases using CRISPR technology [3]. - The company holds exclusive licenses for the Cas12a and Cas9 patent estates from the Broad Institute and Harvard University for human medicines [3]. Presentation Details - The presentation will take place on November 8, 2025, from 10:45 a.m. to 11:45 a.m. CT, under the session title "Cutting-Edge Gene and Precision Therapies" [2]. - Anshul Gupta, Vice President of Preclinical Development at Editas Medicine, will be the presenter [2]. - The accepted abstract and poster presentation will be available on the AHA website and the company's website, respectively [2].

Core Insights - Editas Medicine, Inc. is set to present a transformative LDL-cholesterol-lowering in vivo CRISPR gene editing medicine at the European Society of Gene and Cell Therapy (ESGCT) Congress in Seville, Spain from October 7-10, 2025 [1][2] Company Overview - Editas Medicine is a pioneering gene editing company focused on developing transformative in vivo medicines for serious diseases using CRISPR technology [4] - The company holds exclusive licenses for the Cas12a and Cas9 patent estates from the Broad Institute and Harvard University for human medicines [4] Upcoming Events - The oral presentation at ESGCT will take place on October 9, 2025, at 5:00 p.m. CEST, with the final abstract number OR069 [2] - Management will also participate in investor conferences in October, including a virtual fireside chat on October 14 and a panel discussion on October 21 in New York [3][5]